World Journal of Dentistry

Register      Login

VOLUME 15 , ISSUE 4 ( April, 2024 ) > List of Articles

ORIGINAL RESEARCH

Effectiveness of Injectable Platelet-rich Fibrin on Interleukin-6 Levels in Chronic Periodontitis with Type II Diabetes: A Randomized Controlled Trial

Nivethaprashanthi Swaminathan, Senthilnathan Sivaramalingam, Gayathri Haritheertham, Thirumalai Sankaralingam, Ahila Elumalai, Hema Pannerselvam

Keywords : Chronic periodontitis, Gingival crevicular fluid, Injectable platelet-rich fibrin, Interleukin-6 levels, Randomized controlled trial, Scaling and root planing, Type II diabetes

Citation Information : Swaminathan N, Sivaramalingam S, Haritheertham G, Sankaralingam T, Elumalai A, Pannerselvam H. Effectiveness of Injectable Platelet-rich Fibrin on Interleukin-6 Levels in Chronic Periodontitis with Type II Diabetes: A Randomized Controlled Trial. World J Dent 2024; 15 (4):281-287.

DOI: 10.5005/jp-journals-10015-2411

License: CC BY-NC 4.0

Published Online: 17-05-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Abstract

Aim: To compare the levels of gingival crevicular fluid (GCF) interleukin-6 (IL-6) with and without adjunctive injectable platelet-rich fibrin (i-PRF) after scaling and root planing (SRP) in chronic periodontitis patients with type II diabetes. Materials and methods: This was a split-mouth, double-blinded study conducted on 35 chronic periodontitis patients with well-controlled type II diabetes [glycated hemoglobin (HbA1C) value 6.5–7.5%]. The sites were randomly allocated into two groups—group I, i-PRF adjunct to scaling and root planning, and group II, scaling and root planning alone. The clinical attachment level (CAL), probing pocket depth (PPD), gingival bleeding index (GBI), and plaque index (PlI) were recorded at baseline, 1 month, and 3 months. GCF was collected at baseline and 1 month and subjected to enzyme-linked immunosorbent assay (ELISA) for the evaluation of IL-6 levels. Data were statistically analyzed using Jeffreys's Amazing Statistics Program (JASP) version 14. Results: On intergroup comparison, the clinical parameters showed statistically significant results when compared to baseline, 1 month, and 3 months. On intragroup comparison, the mean CAL for group I reduced from 5.09 ± 0.45 to 2.60 ± 0.55, and for group II, it reduced from 5.03 ± 0.57 to 3.63 ± 0.77. The mean PPD for group I reduced from 5.03 ± 0.57 to 2.60 ± 0.55, and for group II, it reduced from 4.94 ± 0.48 to 3.63 ± 0.77. A significant reduction in mean GBI score and PlI score was observed. The mean IL-6 level showed significant improvement within the groups and was not significant when compared between groups I and II. Conclusion: The i-PRF as an adjunct to SRP provided better results when compared with SRP alone in chronic periodontitis patients with type II diabetes. Clinical significance: The i-PRF is an innovative advancement in the field of dentistry. Due to its easy availability and better properties, it can be implemented in various periodontal procedures and in other fields of dentistry.


PDF Share
  1. Preshaw PM, Alba AL, Herrera D, et al. Periodontitis and diabetes: a two-way relationship. Diabetologia 2012;55(1):21–31. DOI: 10.1007/s00125-011-2342-y
  2. Vučković M, Nikolić N, Milašin J, et al. The effect of injectable platelet-rich fibrin use in the initial treatment of chronic periodontitis. Srp Arh Celok Lek 2020;148(5–6):280–285. DOI: 10.2298/SARH190925022V
  3. Vahabi S, Sattari M, Taheraslani M, et al. Correlation between interleukin-1β, interleukin-6 and tumor necrosis factor-α and clinical parameters in chronic and aggressive periodontal disease. J Adv Periodont Impl Dent 2011;3(2):51–56. Available from: https://japid.tbzmed.ac.ir/Article/jpid-39
  4. Tawfig N. Proinflammatory cytokines and periodontal disease. J Dent Probl Solut 2016;3(1):012–017. DOI: 10.17352/2394-8418.000026
  5. Liu J, Wang Y, Ouyang X. Beyond toll-like receptors: porphyromonas gingivalis induces IL-6, IL-8, and VCAM-1 expression through NOD-mediated NF-κB and ERK signaling pathways in periodontal fibroblasts. Inflammation 2014;37(2):522–533. DOI: 10.1007/s10753-013-9766-0
  6. Kalsi R, Vandana KL, Prakash S. Effect of local drug delivery in chronic periodontitis patients: a meta-analysis. J Indian Soc Periodontol 2011;15(4):304–309. DOI: 10.4103/0972-124X.92559
  7. Ashtaputre V, Limaye M. Local drug delivery in Periodontics: a tactical entreaty. J Res Pharmaceut Sci 2014;2(1):6–11. Available from: https://www.questjournals.org/jrps/papers/vol2-issue1/B210611.pdf
  8. Agrawal DR, Jaiswal PG. Injectable platelet rich fibrin (I-PRF): a gem in dentistry. Int J Curr Res Rev 2020;12(21):25–30. DOI: 10.31782/IJCRR.2020.122116
  9. Kaplish V, Walia MK, Kumar HS. Local drug delivery systems in the treatment of periodontitis: a review. Pharmacophore 2013;4(2):39–49. Available from: https://pharmacophorejournal.com/article/local-drug-delivery-systems-in-the-treatment-of-periodontitis-a-review
  10. Rakhewar PS, Jannawar P, Chacko NL, et al. An evaluation of clinical effects of i-PRF as an adjunctive to non-surgical periodontal therapy versus non-surgical periodontal therapy alone in treatment of chronic periodontitis patients – a split mouth randomized controlled clinical trial. J Dent Med Sci 2021;20(9):11–18. DOI: 10.9790/0853-2009051118
  11. Nakahara T, Nakamura T, Kobayashi E, et al. Novel approach to regeneration of periodontal tissues based on in situ tissue engineering: effects of controlled release of basic fibroblast growth factor from a sandwich membrane. Tissue Eng 2003;9(1):153–162. DOI: 10.1089/107632703762687636
  12. Panda S, Purkayastha A, Mohanty R, et al. Plasma rich in growth factors (PRGF) in non-surgical periodontal therapy: a randomized clinical trial. Braz Oral Res 2020;34:e034. DOI: 10.1590/1807-3107bor-2020.vol34.0034
  13. Noh MK, Jung M, Kim SH, et al. Assessment of IL-6, IL-8 and TNF-α levels in the gingival tissue of patients with periodontitis. 2013;6(3):847–851. DOI: 10.3892/etm.2013.1222
  14. Bibi T, Khurshid Z, Rehman A, et al. Gingival crevicular fluid (GCF): a diagnostic tool for the detection of periodontal health and diseases. Molecules 2021;26(5):1–16. DOI: 10.3390/molecules26051208
  15. Goutoudi P, Diza E, Arvanitidou M. Effect of periodontal therapy on crevicular fluid interleukin-6 and interleukin-8 levels in chronic periodontitis. Int J Dent 2012;2012:362905. DOI: 10.1155/2012/362905
  16. Llambés F, Arias-Herrera S, Caffesse R. Relationship between diabetes and periodontal infection. World J Diabetes 2015;6(7):927–935. DOI: 10.4239/wjd.v6.i7.927
  17. WHO. Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus: Abbreviated Report of a WHO Consultation. Approved by the Guidelines. Review Committee. World Health Organization; 2011;299–309.
  18. Prasad DR, Raj DA, Khan DSF, et al. Effect of non-surgical periodontal therapy on glycemic control of patients with chronic periodontitis and type-2 diabetes mellitus: a 3 month follow-up intervention study. Int J Appl Dent Sci 2021;7(2):05–08. DOI: 10.22271/oral.2021.v7.i2a.1179
  19. Agarwal M, Chaubey K, Madan E, et al. Effect of periodontal therapy on type 2 diabetes mellitus patients with chronic periodontitis with the evaluation of HbA1c. J Int Clin Dent Res Organ 2016;8(1):34. DOI: 10.4103/2231-0754.176248
  20. Zhang H, Li C, Shang S, et al. Scaling and root planing with enhanced root planing on healthcare for type 2 diabetes mellitus: a randomized controlled clinical trial. J Dent Sci 2013;8(3):272–280. DOI: 10.1016/j.jds.2012.10.009
  21. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013;310(20):2191–2194. DOI: 10.1001/jama.2013.281053
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.